Polyposis natural remedy by Ray Sahelian, M.D.
January 20 2016
Familial adenomatous polyposis is an autosomal dominant disorder leading to the development of hundreds of colorectal adenomas and eventual colorectal cancer. These colonic polyposis usually show no symptoms.
Treatment for familial adenomatous polyposis
Regression of adenomas in this syndrome occurs with the administration of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors, but these compounds can have considerable side effects. Natural treatment options with curcumin, quercetin and other natural supplements are just being evaluated.
Natural and alternative therapy
It is exiting to discover that natural supplements could be helpful in the treatment of familial adenomatous polyposis.
Curcumin and quercetin for Familial adenomatous
Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis.
Clin Gastroenterol Hepatol. 2006 August. Cruz-Correa M, et al. Department of Medicine, Cleveland Clinic, Weston, Florida, USA.
We evaluated the efficacy of the combination of diet-derived nonprescription supplements curcumin and quercetin to regress adenomas in patients with familial adenomatous polyposis. Five familial adenomatous polyposis patients with prior colectomy (4 with retained rectum and 1 with an ileal anal pouch) received curcumin 480 mg and quercetin 20 mg orally 3 times a day. The number and size of polyps were assessed at baseline and after therapy. All 5 patients had a decreased polyp number and size from baseline after a mean of 6 months of treatment with curcumin and quercetin. The mean percent decrease in the number and size of polyps from baseline was 60 and 50, respectively. Minimal adverse side effects and no laboratory abnormalities were noted. The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with familial adenomatous polyposis without appreciable toxicity.
Fish oils and omega-3 fatty acids
The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) has anticolorectal cancer activity in vitro and in preclinical models. The present study tested whether a novel, enteric-coated formulation of EPA, as the free fatty acid (EPA-FFA), has chemopreventative efficacy in patients with familial adenomatous polyposis (FAP), in a randomised, double-blind, placebo-controlled trial. Patients undergoing endoscopic surveillance of their retained rectum postcolectomy were randomised to EPA-FFA (SLA Pharma) 2 g daily or placebo for 6 months. EPA-FFA has chemopreventative efficacy in FAP, to a degree similar to that previously observed with selective cyclo-oxygenase-2 inhibitors. EPA holds promise as a colorectal cancer chemoprevention agent with a favorable safety profile. West NJ, Clark SK, Phillips RK, Hutchinson JM, Leicester RJ, Belluzzi A, Hull MA. Section of Molecular Gastroenterology, Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, UK. Gut. 2010 July.
Proc Natl Acad Sci U S A. Feb 10 2014. Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. Tetraploidy constitutes a genomically metastable state that can lead to aneuploidy and genomic instability. Tetraploid cells are frequently found in preneoplastic lesions, including intestinal cancers arising due to the inactivation of the tumor suppressor adenomatous polyposis coli (APC). Using a phenotypic screen, we identified resveratrol as an agent that selectively reduces the fitness of tetraploid cells by slowing down their cell cycle progression and by stimulating the intrinsic pathway of apoptosis. Selective killing of tetraploid cells was observed for a series of additional agents that indirectly or directly stimulate AMP-activated protein kinase (AMPK) including salicylate, whose chemopreventive action has been established by epidemiological studies and clinical trials. Both resveratrol and salicylate reduced the formation of tetraploid or higher-order polyploid cells resulting from the culture of human colon carcinoma cell lines or primary mouse epithelial cells lacking tumor protein p53 (TP53, best known as p53) in the presence of antimitotic agents, as determined by cytofluorometric and videomicroscopic assays. Moreover, oral treatment with either resveratrol or aspirin, the prodrug of salicylate, repressed the accumulation of tetraploid intestinal epithelial cells in the ApcMin/+ mouse model of colon cancer. Collectively, our results suggest that the chemopreventive action of resveratrol and aspirin involves the elimination of tetraploid cancer cell precursors.
Familial polyposis symptom
Symptoms of familiar colonic polyposis are infrequent but could include rectal bleeding, abdominal pain, and diarrhea.
Other types of polyposis
Hamartomatous intestinal polyposis
J Allergy Clin Immunol. 2015. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. Chronic rhinosinusitis (CRS) affects more than 10% of the population in the United States and Europe. Recent findings point to a considerable variation of inflammatory subtypes in patients with CRS with nasal polyps and patients with CRS without nasal polyps. According to current guidelines, glucocorticosteroids and antibiotics are the principle pharmacotherapeutic approaches; however, they fail in a group of patients who share common clinical and laboratory markers. Several clinical phenotypes often leading to uncontrolled disease, including adult nasal polyposis, aspirin-exacerbated respiratory disease, and allergic fungal rhinosinusitis, are characterized by a common endotype: a TH2 bias is associated with a higher likelihood of comorbid asthma and recurrence after surgical treatment. As a consequence, several innovative approaches targeting the TH2 bias with humanized mAbs have been subjected to proof-of-concept studies in patients with CRS with nasal polyps with or without comorbid asthma: omalizumab, reslizumab, mepolizumab, and recently dupilumab.